Compare · HKPD vs MCK
HKPD vs MCK
Side-by-side comparison of Cellyan Biotechnology Co. Ltd (HKPD) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HKPD and MCK operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $116.43B, about 21844.0x HKPD ($5.3M).
- Over the past year, HKPD is down 91.1% and MCK is up 27.8% - MCK leads by 118.9 points.
- MCK has been more active in the news (4 items in the past 4 weeks vs 2 for HKPD).
- MCK has more recent analyst coverage (25 ratings vs 0 for HKPD).
- Company
- Cellyan Biotechnology Co. Ltd
- McKesson Corporation
- Price
- $0.11-1.64%
- $1005.29+0.65%
- Market cap
- $5.3M
- $116.43B
- 1M return
- -11.60%
- +14.29%
- 1Y return
- -91.13%
- +27.82%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 2
- 4
- Recent ratings
- 0
- 25
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest HKPD
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form S-8 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 20-F filed by Cellyan Biotechnology Co. Ltd
- SEC Form NT 20-F filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-3 filed by Cellyan Biotechnology Co. Ltd
Latest MCK
- SEC Form 8-K filed by McKesson Corporation
- CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health
- McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
- McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date
- SVP, Controller & CAO Rutledge Napoleon B Jr sold $98,951 worth of shares (111 units at $891.45) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 521 units (SEC Form 4)
- McKesson Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
- RBC Capital Mkts initiated coverage on McKesson with a new price target
- SEC Form 4 filed by EVP and Chief Strategy Officer Srinivasan Ramesh (Nmn)
- Director Lerman Bradley E sold $268,590 worth of shares (301 units at $892.33), closing all direct ownership in the company (SEC Form 4)